In the BioHarmony Drug Report Database

"Preview" Icon

Pibrentasvir

Mavyret, Maviret (pibrentasvir) is a small molecule pharmaceutical. Pibrentasvir was first approved as Mavyret on 2017-07-26. It is used to treat hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Mavyret’s patents are valid until 2035-06-05 (FDA).

 

Trade Name

 

Maviret
 

Common Name

 

pibrentasvir
 

ChEMBL ID

 

CHEMBL3545123
 

Indication

 

chronic hepatitis c, hepatitis c
 

Drug Class

 

Antivirals: NS5A inhibitors

Image (chem structure or protein)

Pibrentasvir structure rendering